Non Invasive Markers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Johnj suschakJonathan kasperM scot robertsSarahk browneIm scott harrisStephena harrisonDanielle canteyevoke canalephoneShaheen tomahAltimmune incPark cityInduced liver fat reductionNon invasive markersPlacebo controlled trialNon alcoholic fatty liver diseaseRich eisenstadtchief financial officerphone

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

22% and 24% of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group.

United statesSarah oconnellAndrew chengPa fibroscanStephen harrisonAustin murtaghAkero therapeutics incPinnacle clinical researchExchange commissionLiver biopsy analysis setNon invasive markersChange from baselineFull analysisSerum markersConference callSouth san

Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study

Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew chengPa fibroscanStephen harrisonAkero therapeutics incPinnacle clinical researchAkero therapeuticsLiver biopsy analysis setNon invasive markersChange from baselineFull analysisSerum markersConference call

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesStephena harrisonStephen harrisonAltimmune incPinnacle clinical researchFounder of pinnacle clinical researchSummit clinical researchPark cityGlucagon dual receptor agonistSignificantly reduces liver fatNon invasive markersBody weightNon alcoholic fatty liver diseaseMountain standardMedia contacts